GSK Affirms Its FY25 Guidance And Expects Its Turnover To Increase Between 3%-5% And Core Operating Profit To Increase Between 6%-8%. Core EPS Is Expected To Increase Between 6%-8%
GSK Q1 Adj. EPS $1.13 Beats $1.04 Estimate, Sales $9.46B Beat $7.46B Estimate
Dow Surges 300 Points Amid Trade Deal Hopes: Greed Index Remains In 'Fear' Zone
Is it all Trump's fault for wildly swinging the 'tariff club'? Pfizer: Uncertainty has hindered manufacturing and research and development investment.
① Pfizer CEO Albert Bourla stated that the uncertainty surrounding Trump's proposed pharmaceutical tariffs is hindering the company's manufacturing and R&D investments in the USA; ② Bourla emphasized that the company hopes to see "certainty," meaning clear tariffs or additional incentives, to increase investment in the USA.
Labcorp Targets 10% EPS Growth With New Diagnostics and Acquisitions Strategy
What Does the Market Think About AstraZeneca?